Why you should buy this 'industry leading' ASX 200 tech stock

Goldman Sachs thinks investors should be buying this high-quality company's shares.

| More on:
A man and woman in an office look at a laptop and discuss investing, budget strategies or other financial concepts

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Pro Medicus Limited (ASX: PME) shares overcame the market weakness on Tuesday and pushed higher.

The ASX 200 tech stock rose 1% to end the day at $114.31.

Why did this ASX 200 tech stock rise?

Investors were bidding the health imaging technology company's shares higher after it announced five new contracts with a combined minimum contract value of $45 million.

These contracts will be fully cloud deployed and are expected to be completed within the next six months.

The contracts are as follows:

  • A $9.5 million, five-year contract with Consulting Radiology, a private radiology group in Minnesota.
  • An $11.5 million, seven-year contract with Nationwide Children's Hospital. It is a leading paediatric hospital in Columbus, Ohio.
  • A $6.5 million, five-year contract with Nicklaus Childrens Hospital, a leading paediatric hospital in Miami, Florida.
  • A $9 million, eight-year contract with Moffitt Cancer Center in Tampa, Florida.
  • An $8.5 million, five-year contract with US Radiology Specialists. It is a partnership of physician owned radiology practices.

These contract wins bring the company's minimum total contract value (TCV) for new sales this financial year to $245 million.

Broker reaction

This morning, analysts at Goldman Sachs have responded very positively to the news.

According to the note, the broker has reiterated its buy rating with a slightly improved price target of $136.00.

Based on where the ASX 200 tech stock currently trades, this implies a potential upside of 19% for investors over the next 12 months.

Commenting on the contract wins, the broker said:

PME continues to demonstrate Visage's compelling product offering and value proposition to a broadening range of customers across different sizes and specialties (i.e. children's hospitals and private radiology groups where the market is evolving, with more tenders coming to market). This provides a platform for further growth (direct validation & referral effect), supporting a positive TAM runway for Visage which currently commands c.7% market share of US imaging volumes (GSe +13% in FY30E) – a key component of our Buy Initiation in April; (2) All contracts to be fully cloud-based, and we believe Visage is the only solution available that can be fully cloud-deployed at this scale, and hence represents a tangible competitive advantage, as highlighted today; and (3) the announced contract sizes contain no direct component from either AI or Cardiology, which should present upside optionality through the mid-term.

'Industry leading'

All in all, this news reinforces the broker's bullish view on the ASX 200 tech stock and its "industry leading" technology. It concludes:

In our view, PME is well positioned into FY25 given a full year benefit of some large and high profile contracts, in addition to the accelerating frequency and size of new contract wins. We see PME's software Visage 7 as an industry leading solution with two distinct advantages relative to peers — speed and cloud capabilities — that have influenced the choice of PACS vendor. Given this, PME is benefiting from an industry network effect, and we forecast share gains to 13% in FY30E (c.7% today) as more hospitals move to modern systems. PME is expanding into adjacent solutions including AI and Cardiology which could provide significant upside given we believe PME is the incumbent technology leader in radiology, and is well-placed to take share in both markets.

Motley Fool contributor James Mickleboro has positions in Pro Medicus. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group and Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Technology Shares

A young well-dressed couple at a luxury resort celebrate successful life choices.
Technology Shares

Why the 'opportunity is immense' for DroneShield shares: fundie

DroneShield’s 480% one-year share price gains may be just the beginning, according to this top fundie.

Read more »

A man in trendy clothing sits on a bench in a shopping mall looking at his phone with interest and a surprised look on his face.
Technology Shares

3 explosive ASX tech stocks to buy and hold forever

Analysts think very highly of these rapidly growing companies.

Read more »

A group of businesspeople clapping.
Technology Shares

Why Xero could be one the best shares to buy in the Asia-Pacific

Goldman Sachs thinks very highly of this tech stock.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Technology Shares

Up 80% in a year, this ASX All Ords stock is a 'long way short' of its true value

This fund manager is bullish.

Read more »

A smiling woman with a handful of $100 notes, indicating strong dividend payments
Technology Shares

If I'd put $5,000 into DroneShield shares just 1 year ago, here's what I'd have now

How good an investment has this tech company been?

Read more »

Vanadium Resources share price person riding rocket indicating share price increase
Technology Shares

Guess which ASX tech stock could double in value

This highly speculative stock could offer big returns according to one broker.

Read more »

A silhouette shot of a man holding a control in his hands and watching as a drone hovers overhead with sunrays coming from the sky.
Technology Shares

Unstoppable: How much higher can the DroneShield share price fly?

Another day flying high for this counter-drone player.

Read more »

A man sits in deep thought with a pen held to his lips as he ponders his computer screen with a laptop open next to him on his desk in a home office environment.
Share Fallers

Why did this ASX AI stock just crash 21%?

Investors just sent this ASX AI stock tumbling by more than 21%. But why?

Read more »